Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial

BACKGROUND/AIMS: Besifovir dipivoxil maleate (BSV), an acyclic nucleotide phosphonate, shows potent antiviral activity against hepatitis B virus. Our previous 48-week trial revealed that BSV has comparable antiviral efficacy to tenofovir disoproxil fumarate (TDF) and better safety profiles in terms...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Mol Hepatol
Main Authors: Song, Do Seon, Kim, Won, Ahn, Sang Hoon, Yim, Hyung Joon, Jang, Jae Young, Kweon, Young Oh, Cho, Yong Kyun, Kim, Yoon Jun, Hong, Gun Young, Kim, Dong Joon, Jung, Young Kul, Sohn, Joo Hyun, Lee, Jin-Woo, Park, Sung Jae, Lee, Byung Seok, Kim, Ju Hyun, Kim, Hong Soo, Yoon, Seung Kew, Kim, Moon Young, Lee, Kwan Sik, Lim, Young Suk, Lee, Wan Sik, Yang, Jin Mo, Kim, Kyun-Hwan, Han, Kwang-Hyub, Um, Soon Ho
Formato: Artigo
Idioma:Inglês
Publicado em: The Korean Association for the Study of the Liver 2021
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8046633/
https://ncbi.nlm.nih.gov/pubmed/33493393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2020.0307
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados